1767 related articles for article (PubMed ID: 17961178)
1. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
2. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
3. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
Poodt J; Fijnheer R; Walsh IB; Hermans MH
Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
[TBL] [Abstract][Full Text] [Related]
4. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
[TBL] [Abstract][Full Text] [Related]
5. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
6. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB
Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018
[TBL] [Abstract][Full Text] [Related]
7. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
8. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
9. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
10. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
Oh ST; Gotlib J
Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
[TBL] [Abstract][Full Text] [Related]
11. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
12. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
13. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
14. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
16. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
[TBL] [Abstract][Full Text] [Related]
17. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
18. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
19. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA
Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
[TBL] [Abstract][Full Text] [Related]
20. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
